Cardiovascular

Ian Riddock, MD, and Leandro N. Slipczuk, MD, PhD, discuss the importance of LDL-C management as part of the discharge plan for patients, as well as ensuring continuity of care from the inpatient to outpatient setting.

Dr Brinton highlights the importance of adjunct therapies in LDL management.

Dr Riddock explains how the ASCVD treatment landscape lends itself to initiation of therapy beyond statins in the inpatient setting.

Eliot Brinton, MD, provides a warning concerning “maximally-tolerated statin dosing” and provides general guidance for optimal dosing.

Ian Riddock, MD, describes the high-risk patient with ASCVD that is appropriate for early intensive lipid lowering.

Ian Riddock, MD, describes residual cardiovascular risk, both with and without the use of statin therapies.

An expert advises how to optimize the care continuum for patients with ASCVD.

Dr Ian Riddock explains the patient journey post-myocardial infarction (MI), from hospital to outpatient care.

Ian Riddock, MD, discusses the burden of atherosclerotic cardiovascular disease (ASCVD) and multi-societal guideline recommendations for lipid management.

The top 5 most-read conference stories of 2020 on AJMC.com included stories about study results on the impact that new therapies are having on cardiovascular and renal health.

A recent study sought to estimate the incidence of clinical events such as bleeding, myocardial infarction, and all-cause mortality in patients with acute myocardial infarction and chronic coronary syndrome who received dual antiplatelet therapy (DAPT) after coronary stenting.

The distinction between valvular and nonvalvular atrial fibrillation (AF) has been a persistent point of confusion for clinicians.

The American College of Cardiology provides new guidance on the best therapy to prevent blood clots for patients with atherosclerotic cardiovascular disease who also have atrial fibrillation or venous thromboembolism and require an anticoagulant.

Giving patients icosapent ethyl, or Vascepa, led to a 52% reduction of the total patient-reported symptom outcome prevalence score as compared with a 24% decline for outpatients who received usual care.

There was a significant decrease in the rates of cardiovascular complications and mortality in adults with diabetes in South Korea, but other conditions increased.

Despite heavy alcohol consumption being linked to increased incidence of atrial fibrillation (AF) and bleeding in patients with the condition, recommendations to control heavy drinking among this patient population are lacking.

Childhood abuse, household dysfunction, and neglect were linked in a recent study to an increased risk of developing cardiovascular disease in adulthood.

A recent prospective, observational study investigated the use of direct oral anticoagulants for use in patients with postoperative atrial fibrillation and found favorable safety and efficacy results.

The use of a population health management tool may reduce adverse events that may arise from the inappropriate prescribing of direct-acting oral anticoagulants (DOACs).

It remains unclear whether measures of magnetic resonance imaging plaque characteristics are associated with cardiovascular disease events independent of plaque burden at the population level.

Finerenone may represent an important step forward to reducing cardiac illness and death in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), the study said.

The investigator of the STRENGTH study says findings raise questions about the landmark REDUCE-IT trial, but other evidence suggests the drugs involved are different.

Using Plan-Do-Study-Act cycles, the studied intervention reduced hospital inpatient telemetry time by 51.25% while increasing American Heart Association (AHA) guideline–based usage.

The authors report overutilization of telemetry monitoring in a community setting, increasing the cost of health care and potential harm to patients with unnecessary interventions.

Calculating a social score is feasible and it predicts cardiovascular outcomes. In order to do this, institutions have to collect social determinants of health.